Figure 1 — Effectiveness and safety of afatinib, gefitinib, and erlotinib for treatment-naïve elderly patients with epidermal growth factor receptor-mutated advanced non-small-cell lung cancer: a multi-institute retrospective study

Research Paper|Volume 16, Issue 1|pp. 550–567

Effectiveness and safety of afatinib, gefitinib, and erlotinib for treatment-naïve elderly patients with epidermal growth factor receptor-mutated advanced non-small-cell lung cancer: a multi-institute retrospective study

Back to articleFigure 1(1 of 5)

100%

Figure 1.Forest plot of progression-free survival (PFS) and overall survival (OS) of elderly patients (age ≥65 years) treated with afatinib, gefitinib, or erlotinib. Abbreviations: HR, hazard ratio; CI, confidence interval.